2m 2m 2m 2m 2m 2m 2m
KESTRA MEDICAL (KMTS)
NASDAQ
$22.85+$0.02 (+0.09%)
Price as of Aug 03, 2026 7:32 AM EDT- $1.3BMarket Cap
- 48.44%1-Year Change
- Medical Instruments & SuppliesIndustry
KESTRA MEDICAL (KMTS)
$22.85+$0.02 (+0.09%)
Annual
Quarterly
04/30/2026 | 04/30/2025 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 95.1M +59.03% | 59.8M N/A | |
Cost of Revenue | 46.3M +29.93% | 35.6M N/A | |
Gross Profit | 48.9M +101.83% | 24.2M N/A | |
Sales and Marketing Expense | 164.1M +42.79% | 114.9M N/A | |
Research and Development Expense | -19.5M +24.48% | -15.7M N/A | |
Depreciation and Amortization Expense | 8.7M +9.30% | 8.0M N/A | |
Total Operating Expenses | 183.6M +40.60% | 130.6M N/A | |
Operating Profit | -134.7M +26.66% | -106.4M N/A | |
Interest Income | 8.4M +161.05% | 3.2M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 8.4M +161.05% | 3.2M N/A | |
Total Nonoperating Income and Expense | 2.6M +194.65% | -2.8M N/A | |
Income before Taxes | -131.3M +15.52% | -113.7M N/A | |
Income Taxes | 294,000 +117.78% | 135,000 N/A | |
Extraordinary Items | N/A N/A | 0 N/A | |
Net Income | -131.6M +15.64% | -113.8M N/A | |
Net Income from Continuing Operations Applicable to Common | -131.6M +4.34% | -126.1M N/A | |
Basic EPS and Net Income | -2.43 -52.63% | -5.13 N/A | |
Diluted EPS and Net Income | -2.43 -52.63% | -5.13 N/A | |
Basic Weighted Average Shares | 54.2M +120.41% | 24.6M N/A | |
Diluted Weighted Average Shares | 54.2M +120.41% | 24.6M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 20.0M -91.58% | 237.6M N/A | |
Short-Term Investments | 96.7M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 116.7M -50.87% | 237.6M N/A | |
Total Current Assets | 222.4M -12.91% | 255.3M N/A | |
Accumulated Depreciation | 31.4M +31.19% | 24.0M N/A | |
Property and Plant and Equipment and Net | 59.1M +69.65% | 34.8M N/A | |
Total Long-Term Assets | 5.8M +402.17% | 1.2M N/A | |
Total Assets | 358.5M +21.21% | 295.7M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 50.4M +32.64% | 38.0M N/A | |
Total Long-Term Debt | 42.6M +3.77% | 41.1M N/A | |
Total Long-Term Liabilities | 306,000 +118.57% | 140,000 N/A | |
Total Liabilities | 98.8M +9.37% | 90.3M N/A | |
Retained Earnings | -651.9M +25.30% | -520.2M N/A | |
Total Stockholders Equity | 259.7M +26.41% | 205.4M N/A | |
Total Shares Outstanding | 58.4M +13.70% | 51.3M N/A | |
Cash Flow | |||
Cash from Operating Activities | -81.7M +5.28% | -77.6M N/A | |
Capital Expenditures | 34.9M +52.13% | 22.9M N/A | |
Cash from Investing Activities | -203.3M +772.13% | -23.3M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 147.1M -55.46% | 330.3M N/A | |
Financials Ratio | |||
Gross Margin | 51.37% N/A | N/A N/A | |
Operating Margin | -141.64% N/A | N/A N/A | |
Return on Assets | -40.24% N/A | N/A N/A | |
Return on Equity | -56.60% N/A | N/A N/A | |
Revenue Growth | 59.03% N/A | N/A N/A | |
Current Ratio | 4.41 N/A | N/A N/A | |
Cash Ratio | 0.40 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow